Growing Multi-National Pharmaceutical Company Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Informa
November 24 2003 - 9:38AM
PR Newswire (US)
Growing Multi-National Pharmaceutical Company Signs Agreement with
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Award Totals Approximately $1 Million for
Thorough Phase I ECG Study to be Completed Within 90 Days
PHILADELPHIA, Nov. 24 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an
agreement for approximately $1 million in cardiac safety monitoring
and services from a growing multi-national pharmaceutical
organization for one of its drug candidates in clinical trials. The
agreement covers an extensive Phase I study for which eRT is
providing comprehensive support including the provision, training
and ongoing assistance required for effective use of digital
12-lead ECG recording equipment, which is designed to facilitate
the collection of cardiac safety data that are subsequently
provided to eRT for analysis. eRT will perform digital collection,
measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT workflow-enabled data handling
technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and
technical standards. The study is targeted for completion within 90
days of the start date, which should be at the end of the year.
"This significant agreement is the second contract for a Thorough
Phase I ECG Study that has been awarded to eRT by this sponsor in
less than five months," said Scott Grisanti, senior vice president
of business development and chief marketing officer at eRT.
"Regulatory momentum has resulted in the rapid emergence of this
new study type, which requires ECG core laboratories, such as eRT,
to manage recording, analysis and distribution of large volumes of
cardiac safety data in a compressed timeframe. eRT continues to
distinguish itself as the thought and market share leader in this
important new industry segment, which is critical to accelerating
the introduction of new drugs to market safely." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-760-487-1137, for eResearchTechnology, Inc. Web
site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024